Expert Ratings
Easily search Stocks, Mutual Funds, Articles and Videos
Track the companies of Group.
| Sales Growth | Profit Growth | Expense Growth | Stock Price CAGR |
|---|---|---|---|
Presentation & Earning Calls |
Annual Reports |
Credit Rating |
|---|---|---|
|
|
|
|
Concord Biotech was originally incorporated as ‘Servomed Pharmaceuticals Private Limited’ (Servomed) at Ahmedabad, Gujarat as a private limited company under the Companies Act, 1956, pursuant to a certificate of incorporation dated November 23, 1984, issued by the Registrar of Companies, Gujarat, at Ahmedabad (RoC). Servomed was authorized to carry out business of manufacturing, producing, refining, importing, exporting, dealing, distributing, wholesaling, retailing etc. of drugs, medicines, cosmetics, baby food, pharmaceuticals, antibiotics and similar or allied products. At the time of its incorporation, Servomed had three directors, namely, Surendra Shah, Madhukant Shah and Indravadan Shah. An application dated June 24, 1985 was filed for undertaking the change in the name of the company to ‘Concord Pharmaceuticals Private Limited’ as the name ‘Concord’ was capable of being easily pronounced and popularized in the pharmaceuticals industry, pursuant to which a revised certificate of incorporation dated September 24, 1985 was issued by the RoC. Subsequently, with effect from December 26, 1986, Concord Pharmaceuticals Private Limited deemed to have become a public company pursuant to Section 43A of Companies Act, 1956. Thereafter, the name of the company was changed to ‘Concord Biotech Limited’ as the new management of the company decided to use the available plant and machinery for biotechnology products, and a fresh certificate of incorporation dated February 16, 2001 was issued by the RoC. Subsequently, the company became a public company from a deemed public company and a fresh certificate of incorporation dated November 7, 2001 was issued by the RoC.
It is an India-based biopharma company and one of the leading global developers and manufacturers of select fermentation-based APIs across Immunosuppressants and oncology in terms of market share, based on volume in 2022 (Source: F&S Report), supplying to many countries including regulated markets, such as the United States, Europe and Japan and India. It commanded a market share of over 20% by volume in 2022 across identified fermentation-based API products, including mupirocin, sirolimus, tacrolimus, mycophenolate sodium and cyclosporine. In 2016, it launched its formulation business in India as well as emerging markets, including Nepal, Mexico, Indonesia, Thailand, Ecuador, Kenya, Singapore and Paraguay, and have further expanded to the United States.
It manufactures (i) bio-pharmaceutical APIs through fermentation and semi-synthetic processes, across the therapeutic areas of immunosuppressants, oncology and anti-infectives; and (ii) formulations, which are used in the therapeutic areas of immunosuppressants, nephrology drugs and anti-infective drugs for critical care. APIs are active pharmaceutical ingredients which have effects such as preventing or curing diseases. Formulations refer to drug products that are used by patients, such as tablets, capsulesor injections. Immunosuppressants are drugs that are typically used by patients undergoing organ transplants, as these drugs suppress the immunity of the patient such that the body accepts the transplanted organ.
Business area of the company
The company is an India-based biopharma company and one of the leading global developers and manufacturers of select fermentation-based APIs across Immunosuppressants and oncology.
Products of the company
Immunosuppressant
Anti-bacterials
Anti-fungals
Oncology drugs
History and milestone
Comment